Logo

Suggestions

  • Cancer Disparities
  • Opinion
  • Conferences
  • News
  • Patient Corner
  • About
    • Contact
    • Article Submission
  • Top Headlines
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • GI Malignancies
      • Melanoma & Skin Cancer
      • GU Malignancies
      • Gynecologic Oncology
      • Hematologic Malignancies
      • Lung Cancer
  • Expert Opinion
  • Video News
  • New Approvals
  • Cancer Disparities
  • Patient Corner
  • Subscribe

Logo

Expert Opinion

January 26, 2023
Breast Cancer/News/Opinion

DESTINY-Breast04 Trial

By Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School   “Overall, a major shift in the way we treat breast cancer has occurred in 2022, with the demonstration that patients with tumors

Hematologic Malignancies/Opinion

AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia

Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic   In the phase III AGILE trial reported in the New England Journal of Medicine, Pau Montesinos, M.D., Ph.D., and colleagues found that the

January 31, 2023

CheckMate-722: Nivolumab plus Chemotherapy versus Chemotherapy in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer with Disease Progression after EGFR Tyrosine Kinase Inhibitors

Lung Cancer/Opinion

By Dr. Dipesh Uprety Karmanos Cancer Institute   While immunotherapy is being used religiously for non-oncogene-addicted advanced non-small cell lung cancer, the activity of

Neoadjuvant-Adjuvant or Adjuvant Only Pembrolizumab in Advanced Melanoma

Melanoma & Skin Cancer/Opinion

By Dr. Radhika Kulkarni Henry Ford Cancer Institute   On March 2nd, 2023, results of the Phase 2 trial, SWOG 1801, (NCT03698019) were published

Breast Cancer/Opinion

Oral SERD Elacestrant is now an option for metastatic hormone-receptor positive breast cancer: Findings from the Phase III EMERALD Trial

By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center   Endocrine therapy is the mainstay of the management of hormone receptor (HR) positive breast cancer. Until now, fulvestrant remained the only selective

More
by Tiani Grosso
March 27, 2023
Radhika_Kulkarni
Melanoma & Skin Cancer/Opinion

Neoadjuvant-Adjuvant or Adjuvant Only Pembrolizumab in Advanced Melanoma

By Dr. Radhika Kulkarni Henry Ford Cancer Institute   On March 2nd, 2023, results of the Phase 2 trial, SWOG 1801, (NCT03698019) were published in the New England Journal of Medicine. This

More
by Tiani Grosso
March 20, 2023
Lung Cancer/Opinion

CheckMate-722: Nivolumab plus Chemotherapy versus Chemotherapy in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer with Disease Progression after EGFR Tyrosine Kinase Inhibitors

By Dr. Dipesh Uprety Karmanos Cancer Institute   While immunotherapy is being used religiously for non-oncogene-addicted advanced non-small cell lung cancer, the activity of immunotherapy in oncogene-addicted non-small cell lung cancer is

More
by Tiani Grosso
March 20, 2023
Lung Cancer/Opinion

De-escalating Therapy in Human Papillomavirus-Related Oropharyngeal Cancer

By Dr. Tarik Hadid Wayne State University   Human papillomavirus (HPV) is a small DS-DNA virus, and humans are the only known hosts. There are around 200 subtypes of the virus that

More
by Tiani Grosso
March 9, 2023
GU Malignancies/Opinion

The CALYPSO Study Tests the Combination of MET and PD-L1 Inhibition in Patients with Advanced Papillary Renal Cancer

By Dr. Inas Abuali Massachusetts General Hospital   There is a paucity of available treatment options for patients with advanced papillary renal cancer (PRC), a disease characterized by aggressive features and a

More
by Tiani Grosso
March 7, 2023
Hematologic Malignancies/Opinion

AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia

Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic   In the phase III AGILE trial reported in the New England Journal of Medicine, Pau

More
by Tiani Grosso
January 31, 2023
Breast Cancer/News/Opinion

DESTINY-Breast04 Trial

By Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School   “Overall, a major shift in the way we treat breast cancer has occurred in 2022, with the demonstration that patients with tumors

More
by Tiani Grosso
January 26, 2023
Medicaid-expansion-graph
News/Opinion

The Cure for Expertise Loneliness

In this blog article, Dr. Dan Milner, Chief Medical Officer of the American Society for Clinical Pathology, discusses his experience about his participation in the 2022 Summit on Cancer Health Disparities held

More
by Staff Writer - The Cancer News
May 20, 2022

your advertisement here

you may also like...

  • Oral SERD Elacestrant is now an option for metastatic hormone-receptor positive breast cancer: Findings from the Phase III EMERALD Trial
  • FDA_Approved
    FDA Approves Retifanlimab-dlwr for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma
  • Dr. Rubina Suwal of the Binaytara Foundation Cancer Center Receives ASCO International Innovation Grant
  • Dr_Luke_Fletcher
    Zuma 7 trial shows statistically significant overall survival benefit for yescarta
  • Biomarker Testing in Advanced Non-Small Cell Lung Cancer

All Categories

  • Awareness
  • Breast Cancer
  • Cancer Disparities
  • Cancer Research
  • Conference 2023
  • Conferences
  • Events
  • GI Malignancies
  • GU Malignancies
  • Hematologic Malignancies
  • Journal
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Nepal Cancer Center
  • New Drug Applications
  • News
  • Opinion
  • Patient Corner
  • Spotlights
  • Uncategorized
  • Updates
  • Video News
  • Volunteer Spotlight

Search By Keyword

2022 Summit on Cancer Health Disparities ASCO award Binaytara foundation Binaytara Foundation Cancer Center Binaytara Foundation education academy breast cancer BTF cancer cancer care cancer disparities cancer research cancer treatment cancer treatment in Nepal CME community oncologists conference Conferences continuing education Dr. Binay Shah Dr. Rubina Suwal events Expert Opinion faculty highlight FDA approved head & neck cancer surgery in Nepal healthcare equity hematological malignancies Lung cancer Nepal Nepal cancer care oncology oncology CME Opinion SCHD upcoming conferences video news Volunteer

We Transform Cancer Care

Dissect complex information on cancer and disseminate knowledge to healthcare professionals, patients, and caregivers. We want to improve patient outcomes.
Cover the latest research to promote precision oncology and patient-centered care.
Questions? Contact us -
[email protected]

Social Media

Advertisement


Footer Logo
  • Facebook
  • Twitter
  • LinkedIn
  • Email

© 2023 - All Rights Reserved. Binaytara Foundation

  • About
  • Submit an Article
  • Subscribe for updates
  • Editorial Board
  • Privacy Policy
  • Contact
  • Home
  • Top Headlines
    • Awareness
    • Video News
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • Melanoma & Skin Cancer
      • GI Malignancies
      • Lung Cancer
      • Hematologic Malignancies
      • Gynecologic Oncology
      • GU Malignancies
  • New in Cancer Care
  • Conferences
    • Hemotology & Oncology Conference Calendar
    • Conference Calendar
    • Conference Coverage
  • New Approvals
  • Contact us
  • Submit an article